Oklo

Oklo's stock fell to a 52-week low of $36.61, trading 81% below its year high; the decline over the past year is 55.36%. For Q2 2026, Oklo reported revenue of $1.2 million, beating expectations, while adjusted EPS of -$0.28 missed forecasts. The company closed the quarter with $3.0 billion in cash and announced an at-the-market offering of up to $1 billion plus higher spending to accelerate projects. Truist cut its price target to $51 and reiterated a "Hold" rating, while investors watch for next steps to strengthen the operational and financial position. » More on de.investing.com

Oklo reports that its Groves isotope test reactor has achieved initial criticality after initiating a controlled, low-power, self-sustaining chain reaction. The milestone came less than a year after groundbreaking and concerns the first reactor in the DOE reactor pilot program to be built from the ground up on private land. The project aims to strengthen domestic isotope production and provided experience in construction, operation, fuel procurement, and safety and qualification work. » More on de.investing.com

Oklo has received approval from the U.S. Department of Energy to load nuclear fuel and begin operation of its Groves isotope test reactor. The project, approved under the DOE Reactor Pilot Program, demonstrates reactor operation for planned domestic isotope production for medicine, industry, research, spaceflight and national security. The approval follows a successful readiness review and covers construction, personnel qualification, procurement of fuel and equipment, and implementation of operational and safety programs. » More on de.investing.com